Navigation Links
Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
Date:10/7/2008

Vaccine Has Potential to Save Millions of Lives

GERMANTOWN, Md., Oct. 7 /PRNewswire/ -- Integrated BioTherapeutics Inc. (IBT), a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, announced they have been awarded a multiyear contract for advanced development of a vaccine to protect against Ebola and Marburg viruses from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract is valued at approximately $22 million, which, if options are exercised, could total up to $65 million.

Considered a significant bioterrorist threat, Ebola and Marburg lead to death 30-90 percent of the time they are contracted, and there are currently no vaccines or therapeutics available for treatment of humans infected with either virus. Ebola and Marburg virus outbreaks typically occur in resource poor areas in Sub-Saharan Africa, although rare cases have occurred in the United States, Europe and the Philippines. Filoviruses are also a source of concern as potential bioterror agents.

"We are very pleased that NIAID has awarded such a significant contract to fund the advanced development activities for our virus-like particle vaccine against Ebola and Marburg viruses. This is a significant step forward in our mission to improving public health and developing medical countermeasures for biodefense. This contract will fund a major portion of the preclinical and clinical activities required to confirm and refine the activity in animals and verify the activity in humans," commented Dr. Javad Aman, IBT President and Chief Scientific Officer.

IBT is collaborating with colleagues at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop a subunit vaccine, based on the virus-like particles, with broad-spectrum activity toward different strains of Ebola and Marburg viruses. Other col
'/>"/>

SOURCE Integrated BioTherapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
4. Chiltern Early Phase: Fully Integrated and Business Ready
5. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
6. A first in integrated nanowire sensor circuitry
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
10. Augusta Systems Technologies Integrated into Ciscos Newly Launched Safety and Security Platform
11. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, 2014 /PRNewswire/ ... sponsor for MassBio,s 20th Annual Golf Classic, a major ... The event will be held on September 5 at ... Massachusetts . The MassBioEd Foundation ... through educational programs, workforce development, and lifelong ...
(Date:9/2/2014)... a billionth of a meter in size, are around ... benefit human health, as in some innovative early cancer ... viruses, air pollution, traffic emissions, cosmetics, sunscreen and electronics. ... St. Louis, led by Lan Yang, PhD, the Das ... Engineering, and their collaborators at Tsinghua University in China ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... ... ... var shortURL = ""; BitlyCB.alertResponse ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
... in a row, a pair of Rensselaer students took ... held by the American Society of Mechanical Engineers (ASME). ... Jaron Kuppers won top honors in the national competition ... process. The SET process offers a new method for ...
Cached Biology Technology:YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 2YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 3YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 4YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 5YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 6YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 7YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 8YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 9Medivir: R&D Day 2Medivir: R&D Day 3Medivir: R&D Day 4Medivir: R&D Day 5Medivir: R&D Day 6Medivir: R&D Day 7Medivir: R&D Day 8Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
(Date:9/2/2014)... Cancer Center researchers may have discovered a new way ... vulnerable by deficient DNA repair. , The findings were ... , The study, led by James E. Hansen, ... of Medicine, found that cancer cells with deficient DNA ... genetic damage) were significantly more vulnerable to attack by ...
(Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2
... assessment of malnutrition, created by researchers at Penn State, ... diagnosis and treatment. Up to 50 percent of ... be malnourished, according to Gordon Jensen, professor and head ... confusion exists in the clinical community on how to ...
... seeking to refine and improve lung-cancer screening by combining a ... more effectively. The trial combines a CT chest scan and ... to build on recent research demonstrating that CT screening alone ... CT screening of high-risk patients can reduce lung-cancer deaths. But ...
... heel within our cells that bacteria are able to exploit ... their findings could lead to the development of new anti-infective ... resistance. University of Manchester researchers studied Listeria ... listeriosis in humans when digested and found they are ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The Experion Pro260 analysis kit for 10 ... to perform protein analysis with the Experion ... Pro260 microfluidic chips, 3 x 520 microliters ... microliters Pro260 ladder (10-260 kD), 400 microliters ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and reliable ... proteomics and drug development laboratories. Staccato ... instrumentation to automate basic liquid handling ... are controlled with either Caliper's time ...
Biology Products: